Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Randomized, Double Blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis (AD)

NCT07235384 is registered in ClinicalTrials.gov with Zai Lab (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07235384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07235384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Randomized, Double Blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis (AD)
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 1, 2025
Completion date
December 28, 2027
Enrollment
84 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad)